Astrazeneca 2025 Q1 Earnings Robust Net Income Growth of 34%

Astrazeneca (AZN), ranking 45th by market capitalization reported its fiscal 2025 Q1 earnings on Apr 28th, 2025. Astrazeneca's fiscal Q1 2025 earnings exceeded expectations, showcasing a strong 34% increase in net income to $2.92 billion compared to the previous year. The company's guidance remains in-line, anticipating high single-digit revenue growth and low double-digit EPS growth. This performance underscores Astrazeneca's operational resilience despite market challenges, reinforcing its commitment to achieving ambitious revenue goals by 2030.
Revenue
Astrazeneca's total revenue rose by 7.2% to $13.59 billion in Q1 2025, compared to $12.68 billion in Q1 2024. The Oncology segment contributed $5.64 billion, with Tagrisso at $1.68 billion, Imfinzi at $1.26 billion, and Calquence at $762 million. Lynparza added $726 million, Enhertu $596 million, and Zoladex $293 million, while Truqap and Imjudo contributed $132 million and $80 million respectively. Datroway brought in $4 million and other oncology $110 million. BioPharmaceuticals, CVRM, generated $3.25 billion, with Farxiga at $2.06 billion, Crestor at $317 million, and Brilinta at $305 million. Seloken/Toprol-XL and Lokelma added $161 million and $153 million, with Roxadustat at $79 million and Wainua at $39 million. Other CVRM totaled $136 million. BioPharmaceuticals, R&I, recorded $2.08 billion, led by Symbicort's $723 million, Fasenra's $418 million, and Breztri's $300 million. Tezspire contributed $217 million, Pulmicort $158 million, and Saphnelo $136 million, with Airsupra at $28 million and other R&I at $104 million. BioPharmaceuticals, V&I, reached $225 million, equally split between Beyfortus and Synagis at $112 million each, with other V&I at $1 million. The Rare Disease segment achieved $2.04 billion, with Ultomiris at $1.05 billion, Soliris $444 million, Strensig $352 million, and Koselugo $138 million. Other Rare Disease amounted to $58 million. Other Medicines brought in $272 million, Nexium $233 million, and others $39 million, with Farxiga sales milestones at $74 million.
Earnings/Net Income
Astrazeneca's EPS rose 33.3% to $1.88 in 2025 Q1 from $1.41 in 2024 Q1, marking continued earnings growth. Meanwhile, the company's profitability strengthened with net income of $2.92 billion in 2025 Q1, marking 34.0% growth from $2.18 billion in 2024 Q1. Remarkably, the company has sustained profitability for more than 20 years over the corresponding fiscal quarter, underscoring strong operational resilience.
Price Action
The stock price of Astrazeneca has edged down 0.46% during the latest trading day, has climbed 4.53% during the most recent full trading week, and has dropped 3.84% month-to-date.
Post Earnings Price Action Review
The earnings report disclosure's impact on Astrazeneca (AZN) shows mixed results in the short term. Despite a 55.56% win rate over three days post-report, average returns were negative at -0.07%. However, longer-term prospects look promising, with 10-day and 30-day win rates at 61.11%, delivering average returns of 1.04% and 0.81%, respectively. The maximum return observed within 30 days was 4.36%, indicating potential opportunities despite initial volatility post-release. Investors may benefit from Astrazeneca's broader-term growth prospects.
CEO Commentary
Pascal Soriot, Chief Executive Officer of AstraZeneca, expressed confidence in the company's strong growth momentum, highlighting that the first quarter of 2025 saw significant advancements in both revenue and clinical developments. He noted that the company is entering a "catalyst-rich period," underscoring the impact of recent positive Phase III study results, including the notable DESTINY-Breast09 and MATTERHORN trials. Soriot emphasized AstraZeneca's commitment to investing in the U.S. market and expanding its global manufacturing footprint, aligning with the ambition to achieve $80 billion in total revenue by 2030.
Guidance
AstraZeneca maintains its fiscal 2025 guidance, expecting total revenue to increase by a high single-digit percentage and core earnings per share (EPS) to grow